Walking to Conquer Melanoma: Mike’s Miracle Workers
By Mara Klecker Even when the pandemic forced the KDB Melanoma 5k Walk/Run to go virtual in 2020, Mike’s Miracle…
Walking to Conquer Melanoma: Mike’s Miracle Workers
By Mara Klecker Even when the pandemic forced the KDB Melanoma 5k Walk/Run to go virtual in 2020, Mike’s Miracle…
,
,
Shannon Eberly, Stage IV Melanoma Survivor- Sharing is Everything
By Mara Klecker Shannon Eberly is fair-skinned and freckled, but she never had a mole on her skin that looked…
,
Steve Banks, Stage III Survivor, Doesn’t Let Melanoma Define His Life
…doctors removed his primary site of melanoma about a decade ago. “I’m an upfront and honest person,” Steve said. “But…
,
Regeneron Reports Fianlimab plus Libtayo Showed Above 60% Response Rate in Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 Inhibitors
…melanoma,” said Israel Lowy, M.D., Ph.D., Senior Vice President, Translational and Clinical Sciences, Oncology at Regeneron. “Combining LAG-3 and PD-1…
,
Diagnosed with Melanoma as a Teenager Changed My Life’s Course
…than 1% of all new cases of melanoma. Madison’s doctor said she was the youngest melanoma patient he’d ever treated.…
,
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
,
,
Reva Foy: Living Her Best Life, Despite Melanoma
…healing, she saw a podiatrist. “He took one look and said, ‘I think it’s melanoma,’” Reva remembers about that day…
,
Replimune Announces BLA Acceptance and Priority Review for RP1 for the Treatment in Advanced Melanoma
…patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for anti-CTLA-4 treatment. For more…
,
Hope, Purpose, and Progress: Melanoma Awareness Month with AIM
…ahead. At AIM at Melanoma, our mission is driven by purpose, sustained by hope, and strengthened by an unwavering commitment…
,
Three New Immunotherapy Agents Tested Against Melanoma in Phase 2 Clinical Trials
…resectable melanoma (mel) (NEO-MEL-T): Primary analysis.” Ahmad Tarhini presented, “A phase II randomized study of neoadjuvant pembrolizumab (P) alone or…
,
Recent Posts
Aug. 31, 2026
Women in Melanoma: A New Chapter in Europe
Aug. 31, 2026
The Legal & Financial Side of a Diagnosis: What No One Tells You
Aug. 19, 2026
Positive Phase 3 Results for Personalized mRNA Therapy in Melanoma
Aug. 07, 2026
RP1 Approved: A Long Road to a New Option for Patients
Aug. 06, 2026